Patent 7629462 was granted and assigned to Smithkline Beecham Limited on December, 2009 by the United States Patent and Trademark Office.
Novel substituted pyrimido[4,5-d]pyrimidin-2-one compounds and compositions for use in therapy as CSBP/p38 kinase inhibitors.